TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) sees a more significant dip than broader market: Some facts to know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $53.19, marking a -1.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback